Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($0.68), $0.11 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $32.41 million versus the consensus estimate of $49.23 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.